⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
EXEL News
Exelixis Inc
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
businesswire.com
EXEL
EXEL Industries: Q1 2025–2026 revenue -17.5%
globenewswire.com
EXEL
Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
businesswire.com
EXEL
Insilico Medicine and Qilu Pharmaceutical Reach Near $120 Million Drug Development Collaboration to Accelerate Novel Cardiometabolic Therapies
prnewswire.com
EXEL
Molecular Switch Targeting Therapies Market Research Report 2026: Opportunities in Targeted Drug Delivery Systems and Therapies in Oncology, Autoimmune, Inflammatory, and Neurological Disorders
globenewswire.com
MRK
BMY
AZN
PFE
NVS
LLY
GILD
JNJ
REGN
ABBV
NVO
SNY
VRTX
AMGN
BIIB
INCY
EXEL
SRPT
CRSP
EDIT
NTLA
ALNY
MRNA
BNTX
COHR
IMUX
INSM
CYTK
KODK
LULU
NVDA
GOOG
MSFT
IBM
AMAT
ILMN
ALKS
ACAD
MNKD
TEVA
BHC
XBI
IBB
XLF
XLK
XLV
JAZZ
ACGL
Glioblastoma Multiforme Treatment Market to Worth Over US$ 6.1 Billion by 2033 | Astute Analytica
globenewswire.com
MRNA
BMY
EXEL
NOV
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
businesswire.com
EXEL
Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026
businesswire.com
EXEL
Qiming Venture Partners' Insilico Medicine Successfully Lists on Hong Kong Stock Exchange USA - English APAC - Traditional Chinese APAC - English USA - English
prnewswire.com
EXEL
SCHR
Qiming Venture Partners' Insilico Medicine Successfully Lists on Hong Kong Stock Exchange USA - English APAC - Traditional Chinese APAC - English
prnewswire.com
EXEL
SCHR
ZLAB